Adapalene Gel 0.3% in the Treatment of Atrophic Acne Scars

Galderma

Status and phase: Completed; Phase 2

Conditions: Acne Scars

Treatments: Drug: Adapalene

Study type: Interventional

Funder types: Industry

Identifiers

NCT01213199

RD.03.SPR.29088

Details and patient eligibility

About

The purpose of this study is to assess the efficacy and safety of Adapalene Gel 0.3% in the treatment of atrophic acne scars.

Enrollment: 20 patients

Sex: All

Ages: 18 to 50 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female subjects of any race, aged 18 to 50 years inclusive
• Subjects with a past history of acne and with moderate to severe facial atrophic acne scars

Exclusion criteria

• Subjects with active inflammatory acne lesions
• Subjects with hypertrophic acne scars

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

20 participants in 1 patient group

Differin 0.3%

Experimental group

Description:

Differin® 0.3% Gel Adapalene 0.3% Topical to the face, once daily application in the evening for the first four weeks and twice daily application in the morning and in the evening for the following 20 weeks.

Treatment:

Drug: Adapalene